Protocols

Grail grabs $900M-plus in Series B; Alnylam’s givosiran makes PRIME time

Jeff Huber

→ Menlo Park, CA-based Grail has banked more than $900 million in its first close of a big Series B led by Arch Venture Partners. J&J Innovation made a big contribution, drawn by the upstarts plans to revolutionize the early detection and treatment of cancer. “We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,” said Jeff Huber, Grail’s CEO. “I believe that Grail’s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art Computer Science and Data Science is unparalleled in the field of cancer detection. Our team made tremendous progress in 2016 and I look forward to additional clinical and strategic milestones.”

→ Cambridge, MA-based Alnylam says the EMA has added its RNAi drug givosiran (ALN-AS1), targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias, to its PRIME project for early access. PRIME may put this drug on an accelerated pathway to an early approval.

→ Veloxis Pharmaceuticals says it will close its office in Edison, NJ and concentrate its staff in North Carolina.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->